V estibular schwannomas (VSs) make up 8% of intracranial tumors, with an annual incidence rate ranging from 11 to 22 per million.
This might indicate that alternative mechanisms for deregulating NF2-related functions in schwannoma cells exist, leading us to search for mutations in genes linked to merlin.
In addition, we directed our attention toward another tumor suppressor gene candidate, CAV1, to see whether mutations in this gene or in genes controlling its expression can provide an explanation for its universal downregulation in sVSs. 1 Except for the hereditary disease associated with VS, neurofibromatosis Type 2, little is known about the development of VS. Numerous studies have been conducted in the search for an etiology, but with inconclusive findings. 15, 43, 51, 53 Recently, Agnihotri et al. sequenced the exomes of a limited number of VSs and spinal schwannomas. 3 To gain a better understanding of the underlying pathogenesis of sVS formation, we performed whole-exome sequencing (WES) of sVSs and normal cells to identify tumor-specific mutations.
The increasing use of radiosurgery in treatment of VS has raised concerns in the neurosurgical community about radiation-induced mutational events leading to malignant transformation. 17, 31, 35, 39, 48, 54 So far, a few cases of postirradiation malignant VSs have been described. Our study therefore aimed not only to study sVS, but also in particular to study the mutational status of cases of VS where the tumor had undergone radiosurgery.
Methods

Patients and Specimen Collection
Samples of VS tissue and EDTA-treated blood were obtained from 46 patients who underwent first-time suboccipital resection of a unilateral VS at the Department of Neurosurgery, Haukeland University Hospital, between August 2003 and October 2014 (Table 1) . Five pieces of viable tumor tissue with diameters of 3-5 mm were collected from the intracapsular part of the tumor. This was done in 1 session, and the tissue was collected from 1 tumor area only. Routine histology was done in each case. Eight patients had been treated with Gamma Knife radiosurgery (GKRS) for the same VS. GKRS was performed according to a standardized protocol of 12 Gy to the tumor periphery at minimum 95% coverage. Six patients exhibited cystic VS. Dexamethasone 4 mg, administered orally 4 times for 1 day preoperatively, was routinely given, starting the day before surgery. Written informed consent was received from all patients before tissue harvesting, and the study was approved by the regional ethical committee for medical research in Western Norway. The samples were either immediately snap-frozen or stored at -80° and then transferred to liquid nitrogen in the Bergen Neurosurgical Tissue Bank at Haukeland University Hospital. One tumor-normal pair was found to be an outlier, accounting for a large number of called variants, and was hence investigated with microsatellite-based polymerase chain reaction (PCR) profiling to confirm that the samples were matched.
DNA Extraction
For DNA extraction, tumor tissue was first disrupted using the TissueLyser (QIAGEN) and treated with protease. Next, DNA was extracted using the QIAamp DNA Mini Kit (QIAGEN). DNA from blood was extracted using QIAsymphony (QIAGEN). The DNA quality and quantity were evaluated with 1% SeaKem gel electrophoresis and NanoDrop spectroscopy (Thermo Fisher Scientific), respectively.
Whole-Exome Sequencing
WES was performed as a custom service (HudsonAlpha Institute for Biotechnology). The capture kit was NimbleGen SeqCap EZ Exome Library v3.0, and sequencing was paired-end sequencing (2 × 100 bp) with approximately 85× coverage on Illumina HiSeq. The resulting reads were aligned to the GRCh37/hg19 reference genome with Burrows-Wheeler transform, 27 and the resulting bamfiles were delivered to us.
Bioinformatic Mutation Analyses
We applied the Genome Analysis Toolkit (version 3.2) 33 base quality score recalibration, indel realignment, duplicate removal, and we performed single-nucleotide polymorphism and INDEL calling across all 92 samples simultaneously using variant quality score recalibration according to Genome Analysis Toolkit Best Practices recommendations. 14, 63 For detection of somatic point substitutions with low allelic fraction, we used MuTect. Candidate variants were filtered according to the following criteria: 1) allelic frequency < 0.05 in 1000 g, esp6500 and exac03; 2) repeated alleles < 5, evaluated manually in borderline cases; 3) allelic frequency in tumor > 0.05, allelic frequency in germline < 0.05, sequencing depth > 7, alternative allele > 1, evaluated manually in borderline cases. The allelic frequency threshold was set to exclude normal variants unlikely to be pathogenic. We excluded areas prone to segmental duplication by setting a cutoff value for mapping quality to 30 (phred score).
To increase the likelihood of detecting mutations important to tumorigenesis, we chose to evaluate nonsynonymous single-nucleotide variants (SNVs); frameshift indels; and stop-gain, stop-loss, and splice-site mutations as predicted by ANNOVAR. The missense SNVs also had to be predicted as deleterious/probably damaging/disease causing/functional (positive prediction) by one of the following prediction algorithms used in ANNOVAR: SIFT, PolyPhen 2 HDIV and HVAR, LRT, Mutation Taster, Mutation Assessor, FATHMM, MetaSVM, and MetaLR. GERP++, PhyloP, and SiPhy annotations were used to assess how conserved the mutated sites were across different species.
After filtering of variants, the remaining candidates were validated visually using the Integrative Genomics Viewer. 45, 60 The outlier was subjected to stricter filtering criteria to reduce the number of possible passenger mutations: ≥ 2 of the aforementioned prediction algorithms for nonsynonymous SNVs had to be positive. The variants passing these filtering criteria were used for subsequent analyses. For pathway analyses, we used QIAGEN's Ingenuity Pathway Analysis (IPA). The samples were pooled to detect clustering of mutations in relevant signaling path-ways and functions, as well as investigated on an individual basis. Grouping was also done according to mutational status, NF2 status, GKRS, or cystic appearance to detect differences associated with these characteristics. Identification of conserved and functional regions was done using the following reference sequences: NF2 (NM_000268); USP8 (NM_005154); and CDC27 (NM_001114091).
To describe the status and number of mutational hits in the NF2 gene, all variants called were examined in the Integrated Genomics Viewer regardless of whether they passed the filtering criteria. A region of interest of exon ± 2 bp was defined to increase the likelihood of mutations detected as being pathogenic. In-frame deletions were considered hits. However, synonymous SNVs and intron SNVs outside of splice donor/acceptor sites were not considered hits, because it is hard to predict the outcome of these.
Multiplex Ligation-Dependent Probe Amplification
For detecting copy number variation in the NF2 gene, we performed multiplex ligation-dependent probe amplification (MLPA) according to the manufacturer's protocol with the SALSA MLPA probe mix P044-B2 NF2. 52 Data analysis was performed using the MLPA analysis tool Coffalyser (MRC-Holland). Normal control material included chorionic villi tissue as normal for the tumor tissue and leukocyte DNA from blood donors as control for patient leukocyte DNA. Borderline results were reexamined using SNVs from the WES data to determine whether there was loss of heterozygosity (LOH) in the allele in question.
Microsatellite Instability PCR
Microsatellite instability (MSI) was investigated using standard procedures with PCR amplification and capillary electrophoresis of the mononucleotide markers NR21, NR24, NR27, BAT25, and BAT26. 
Statistical Analysis
Average and median values were calculated, with maximum and minimum values shown in parentheses. The correlation coefficient was also calculated. To determine strength of association between a gene set and NF2, mean values for number of linking pathways and genes were calculated with standard deviations and 95% CIs. To aid in determining copy number variants in NF2, tumor/normal coverage ratios were calculated and normalized using mean exonic coverage for the complete reference exome. For significance analysis regarding linkage to specific 
Results
Patient Cohort
Forty-six patients presenting with sVSs were included in the study (Table 1 ). All patients had unilateral VS, and none had a family history or clinical signs of neurofibromatosis Type 2. The patients in this study were among 160 patients operated on during the period. The 8 patients who had previous radiosurgery were consecutive. The tumor sizes and demographic data of the study patients were within range of all operated cases. The mean age at the time of surgery was 51.3 years, and the mean tumor diameter was 31 mm. Twenty-two patients were men and 24 were women.
The extent of resection was total in 20, near total in 24, and subtotal in 2 patients. Eight patients had poor postresection facial nerve function. All patients had complete hearing loss on the operated side after surgery. The patients receiving subtotal resection got early treatment with salvage radiosurgery. Among the remaining 44 patients, retreatment was given in 1 case due to progression. Follow-up ranged from 2 to 10 years. We succeeded in collecting tissue from all patients who received prior GKRS; these were rare cases and thus were important for the study. The mean time between radiation and microsurgery was 50 months (range 18-114 months). None of the tumors demonstrated MSI.
Whole-Exome Sequencing
To determine the mutational landscape of sVS, tumor DNA and matched normal DNA samples were subjected to WES. The 92 samples (paired tumor and blood samples from 46 patients) had average exome coverage of 91 reads per base; 97% of the reference exome had a coverage of 10× or more, and 95% had a coverage of 20× or more (Supplemental Table 1 ). When 1 outlier accounting for 231 mutations was excluded, a total of 716 mutations affecting 692 genes were identified. A median of 14 (4-57) genes was mutated in each sample (Table 1, Supplemental Fig. 1 ).
Among the 716 mutations, 602 were missense, 51 were stop-gain, 31 were frameshift deletions, 22 were splicesite SNVs, 2 were splice-site indels, 1 was stop-loss, and 7 were frameshift insertions (detailed data on all mutations available upon request). Among 676 SNVs, the most frequent mutations were G>A (n = 172), C>T (n = 160), and G>T (n = 125). Twelve tumors harbored mutations in 13 genes coding for kinases, transcription regulators, or proteases with known inhibitors (Supplemental Table 2 ).
We found no significant correlation between number of mutations and parameters such as diameter of tumor, age, sex, prior GKRS, cystic tumor, or NF2 status. No specific mutation correlated with extent of resection, postresection facial nerve function, or progression-free survival. The number of mutational hits in the NF2 gene did not correlate with the total number of tumor-specific mutations. When stratifying the samples in groups according to number of mutated genes (0-9, 10-19, and ≥ 20 mutated genes), we discovered no significant correlations with given parameters or alterations of pathways.
With the outlier excluded, 3 genes were mutated in > 2 tumors: NF2 (n = 35, 78%), CDC27 (n = 5, 11%), and USP8 (n = 3, 7%). Furthermore, 16 genes were mutated in 2 tumors (4%): CHD4, CTAGE6, CTNNA2, EIF5B, HS6ST1, KALRN, LGR5, LGSN, NAV3, OR2T3, PKD1, PLEC, POTEJ, RAD54B, TENM2, and TTN. The mutations in CDC27 (cell division cycle 27 gene) were clustered in cDNA position 754-796, corresponding to amino acids 252-266 in the predominant isoform, a location between the conserved domains tetratricopeptide repeat 4 and tetratricopeptide repeat 5 that is important for protein-protein interactions. One recurrent mutation (p.G265D) was found in 2 patients. Three tumors (7%) harbored missense mutations in the deubiquitinase gene USP8. The mutations affected a region between amino acids 764 and 798 (corresponding to the ubiquitin-specific protease conserved site region) and were all predicted to be deleterious mutations by several of the prediction algorithms used. None of the tumors harbored mutations in CAV1, but pathway analysis revealed several associations between the gene set and regulation of CAV1 expression.
When pooling the 692 mutated genes from the 45 sVSs, we discovered a significant clustering of mutations in the axonal guidance pathway (Fig. 1) . Twenty-five of 45 patients harbored a mutation in a gene implied in this pathway, with a predominance of missense mutations. None of the genes were mutated in > 2 samples. The next topranked associations between the gene set and canonical pathways included nerve growth factor (NGF) signaling, protein kinase A signaling, breast cancer regulation by stathmin 1, and CDK5 signaling. The 5 top-ranked cellular functions associated with the gene set were cellular growth and proliferation, cellular assembly and organization, cellular function and maintenance, cell morphology, and cellular development ( Table 2 ).
NF2 Status
To determine the somatic status of the NF2 gene in our sVS batch, we investigated for copy number variation by MLPA and mutations from the WES data. In the case of borderline results from MLPA, normalized ratios of coverage on NF2 from tumor/normal pairs were used to aid in determining whether an LOH was present or not. In total, 35 of the 46 (76%) sVSs harbored ≥ 1 somatic mutations in NF2 and 16 of the 46 (35%) harbored 2 mutational hits (Table 3 ). In total, 30 SNVs, 15 small indels, and 11 larger deletions were present, with a predominance of nonsense SNVs, frameshift deletions, and LOH. Three mutations were recurrent throughout the batch (p.W41X, p.R57X, and p.Y132X).
In total, 11 sVSs had no mutations in NF2 (non-NF2). These were examined thoroughly for variants, using filtering criteria that were not as strict. Except for a synonymous SNV detected in 1 sample, no other variants were found. Excluding the single outlier without an NF2 mutation, the 10 remaining sVSs were investigated in silico for linkage between mutated genes in the sample and NF2. One tumor linked directly to NF2 from the transcription factor GATA3, 6 tumors linked indirectly through 1 node, whereas 3 tumors linked through 2 nodes. We further divided the NF2-mutated group into 2 subgroups: 1 NF2 mutation (1hit-NF2, including 19 samples) and 2 NF2 mutations (2hit-NF2, including 16 samples). Overall, 2hit-NF2 had a stronger correlation with molecules upstream of NF2 than 1hit-NF2, although this difference was not significant.
The mean fraction of the genes in each sample in non-NF2 linking to NF2 was 9.6%, and this was comparable with 1hit-NF2 and 2hit-NF2. The recurrent nodes linking genes in the samples in non-NF2 to NF2 were MYC (n = 3), RAC1 (n = 2), ESR1 (n = 2), ubiquitin (n = 2), and GATA3 (n = 2). Although there were some discrepancies between the non-NF2-and the NF2-mutated groups, the recurrent nodes were mostly the same (Fig. 2) . Other recurrent nodes present throughout the 45 sVSs were CDC42 (n = 12), SPP1 (n = 8), CD44 (n = 6), and GRB2 (n = 4). When the mutated genes from the non-NF2 group were pooled, a significant linkage to Schwann cell proliferation (p = 1.02E-03) and NF2 downstream molecules (p = 2.14E-03) was observed. The genes linked to Schwann cell proliferation were spread across 3 samples and included LAMC1, MTOR, CHD4, and ATM. Mutations affecting genes downstream of NF2 were spread across 4 samples and included MTOR, MAPK3, SOS1, PRKAR1B, INADL, and ATM. The NF2-mutated group also exhibited significant linkage to Schwann cell proliferation (p = 3.24E-03) but not to molecules downstream of NF2 (2.62E-01). None of the tumors in the non-NF2 group had a cystic appearance.
For further characterization of the non-NF2 group and comparison with the NF2-mutated group, we identified several canonical pathways (as defined by the IPA Knowl- edge Base) that were differentially associated with the 2 groups (Supplemental Table 3 ). Of note, pathways significantly associated with non-NF2 and not with the NF2-mutated group included insulin receptor signaling, CNTF signaling, EGF signaling, FAK signaling, JAK/Stat signaling, and VEGF signaling, among others. Some of the genes in the non-NF2 group were highly interconnected and linked to several tumorigenesis-related pathways; these included MAPK3, ATM, SOS1, PRKAR1B, ADCY3, MTOR, and WNT6. When dividing the NF2-mutated group into 1hit-NF2 and 2hit-NF2 subgroups, no notable pathway correlated more than expected with 1hit-NF2.
Discussion
To our knowledge, we present here the largest WES study performed on schwannomas. By comparing tumornormal pairs of 46 cases of sVSs, we have elucidated the genetic landscape of this disease. Most intriguingly, the 8 patients with prior GKRS did not demonstrate a higher number of tumor-specific mutations than the rest of the group (Fig. 3) . This is surprising, given the fact that, first, their tumors were radioresistant, which is in itself an uncommon feature of VS, where radiosurgery is successful in approximately 90% of tumors, and that, second, they had been irradiated.
In addition, the types of genes mutated, and the pathways and cellular functions that they were associated with, were largely the same. These results support the findings of a study where previous radiosurgery was not associated with an increased risk of intracranial malignancy. 48 It should be noted, however, that WES would not have detected chromosomal rearrangement due to radiationinduced double-strand breakage of DNA. Gamma Knife treatment of VS is highly effective. All patients who received salvage surgery following GKRS over the study period were included. The low number of patients previously treated with GKRS does not allow for any profound statistical comparisons.
In recent years, several transcriptome studies using microarray techniques have also added to the understanding of this disease. The predominant view regarding sVS pathobiology is that loss of function of merlin, encoded by the NF2 gene, is the main driver of tumorigenesis. However, controversies exist because several reports indicate that a proportion of tumors have an intact NF2 gene and normal mRNA and protein levels. 1, 13, 30 A few studies have demonstrated loss of the protein merlin even in the absence of a mutated gene. 49, 57 Here we report, in agreement with previous studies, that a significant number of the patients had NF2-mutated tumors. NF2 was also established as the main genetic event in schwannoma in the study by Agnihotri et al. 3 However, a subgroup presented without any mutations in this gene.
By means of pathway analysis, we have provided several clues to alternative mechanisms by which tumors that do not harbor NF2 mutations may still have impaired merlin function or impairment of merlin-related functions. In total, 21 tumors linked through either Rac1 and/or Cdc42, proteins belonging to the Rho family of small GTPases that regulate cell growth, organize the cytoskeleton, and activate downstream protein kinases. Constitutively active, Rac1 and Cdc42 phosphorylate Pak, which in turn phosphorylates merlin at S518, impairing its ability to bind its target proteins and thereby enabling it to function as a tumor suppressor. 22, 46, 68 Manchanda et al. also showed that activated Rac1 seemed to suppress merlin protein abundance rather than alter its function. 32 Licciulli et al. identified FRAX597, an inhibitor of Group 1 PAKs, as a potent inhibitor of tumorigenesis in neurofibromatosis Type 2-associated schwannomas, further demonstrating the importance of these molecules. 29 Another recurrent molecule linking our gene set with NF2 is SPP1, which was found to initiate Akt-mediated phosphorylation of merlin at Th230 and S315, leading to its proteasomal degradation. 36 The finding of SPP1 upregulation in a transcriptome study of VS gives further proof of its involvement in merlin depletion in this disease. 61 Our study provides several clues to missing merlin function even in the absence of NF2 mutations. These data thus support the paradigm regarding sVS biology-that NF2 is the main driver of this disease even in the absence of NF2 mutations. The predominance of truncating mutations before missense mutations also lends support to the notion of this gene as a tumor suppressor. However, functional characterization of the mutated forms of these genes and how they affect NF2-related pathways should be investigated.
In our study, we conducted a comprehensive characterization of the mutational status of the NF2 gene and investigated for differential association with distinct pathways and/or defined sets of genes (e.g., molecules downstream of NF2). Although our data suggest that we can stratify the tumors into non-NF2, 1hit-NF2, and 2hit-NF2 subgroups, we cannot say with certainty whether 1 or both alleles
FIG. 2. Recurrent nodes link the sVS gene set with NF2.
The bar graph shows the recurrent nodes in 1-node pathways between sVSs and NF2 discovered using IPA. If one assumed no difference between the non-NF2 and NF2-mutated sVSs, the expected number of non-NF2 genes linking through a specific molecule would be 24% of the total. The graph shows that some of the nodes differ from that assumption, indicating differences between the groups. have mutational hits based on WES data because the 2 hits might occur on the same allele. However, the fact that these mutations are tumor specific suggests that they give the cells a selective advantage. Therefore, it is not unlikely that 2 different mutations in the same patient affect different alleles.
Consistent with the classic Knudson theory of tumor suppressor genes, 7 of the tumors harbored LOH in addition to a small mutational event, indicating hits in both alleles. For the rest of the cases, one might speculate on other causes of impairment of normal merlin function, including epigenetic silencing, post-translational modifications, impairment of RNA splicing, or hits in related pathways and molecules, although epigenetic silencing of NF2 does not seem to be a prevalent event. 25, 26 Another issue to address is the allelic frequency by which the mutations in NF2 occur. If we use VS10 as an illustrative example, one can identify a mutation in both exons 4 and 10 with allelic fractions of 19% and 22%, respectively. If one assumes that these 2 mutations occurred on 2 different chromosomes in the same cell (thereby cohering with the Knudson theory), only 19% of the sequenced DNA from the sample has knocked out NF2. Because these samples are harvested from the subcapsular part and examined by a neuropathologist, except for minor infiltration of blood cells and fibroblasts, these samples consist mostly of tumor cells. Therefore, cellular heterogeneity within the specimens is unlikely to explain the low allelic fraction by which NF2 is mutated. It is tempting to suggest that clonal evolution might also play a role in VS tumorigenesis because it has been proven to be important in several other tumors; our results warrant further investigations on the subject. 16 The correlation between the gene set and regulation of NF2 did not differ between the non-NF2 and NF2-mutated groups. However, we observed a more significant correlation between the non-NF2 group and molecules downstream of NF2 as well as several tumorigenesis-related pathways, further suggesting alternative alterations in a group of sVSs with normal NF2. One of these pathways, insulin receptor signaling, has been implicated in VS tumorigenesis. 2, 5 Our results imply that this pathway may be more important in VSs lacking mutational hits in the NF2 gene.
Another pathway implicated in VS tumorigenesis, ERK/MAPK signaling, was significantly associated with non-NF2, but not with the NF2-mutated group. 1, 4 This suggests that the non-NF2 group carries some mutations that might explain why these patients still develop VS despite not having NF2 mutations. When extracting 1hit-NF2, no notable pathways were identified, suggesting that these cases harbor a second hit in NF2 not identified in the WES or MLPA data. For example, MLPA might not be sensitive enough to identify low allelic fraction deletions, and WES might miss deep intronic variants that are important for RNA splicing.
With the exception of NF2, all genes are mutated at a low percentage, indicating that deregulation of key pathways, rather than mutations of single genes, could be important. Our results demonstrate clustering of mutations in the axonal guidance pathway, suggesting that it may be a driver of sVS tumorigenesis. Torres-Martin et al. made a similar discovery using transcriptome data from 28 sVSs and 3 familial VSs. 61 This pathway, traditionally described in embryonic development, has recently been implicated in tumorigenesis and thus warrants further functional characterization in VS. 7, 34 We also demonstrated mutations in genes coding for proteins with known pharmacological inhibitors in 12 patients. However, to make use of these data in a translational manner, the mutations need to be functionally characterized. These mutations are present in only 1 patient each, making a large-scale cost-efficient screening method for functional characterization of mutations necessary.
Interestingly, we identified 2 novel genes that were mutated in > 2 of the 45 nonoutlier sVSs. One of them, mutated in 5 samples, is CDC27, a component of the anaphasepromoting complex. The protein product from this gene is suggested to be a tumor suppressor, making it a possible driver in a subset of sVSs. 40 Missense mutations in the deubiquitinase gene USP8 were identified in 7% of the tumors in our study. The mutations were clustered in or near the ubiquitin-specific protease-conserved site region and were all predicted as deleterious by the algorithms used. The protein product of this gene is required to enter the S phase of the cell cycle, positively regulates the hedgehog signaling pathway (which is implicated in tumorigenesis), and is thought to inhibit receptor tyrosine kinase degradation. 20, 38, 67 Row et al. reported that knockdown of this product inhibited the degradation of EGFR, whereas Reincke et al. reported that a missense mutation in the 14-3-3 binding motif (amino acids 713-720) enhanced EGFR recycling and activity in corticotroph pituitary adenomas. 44, 47 These results indicate that mutations in this gene are likely to have an effect on functions relevant to tumorigenesis. The ERK pathway, a pathway regulated by EGFR among others, has previously been implicated in sVS pathobiology. 1 One possible explanation is that a subset of sVSs harbors USP8 mutations that impair its normal function and thereby augment ERK signaling and proliferation.
Agnihotri et al. reported that ARID1A and ARID1B mutations were recurrent events, although there was some discrepancy between the frequency of mutated samples in the WES experiment and in Sanger sequencing. 3 As the authors suggested, the relatively high number of mutations detected in the validation cohort might reflect novel single-nucleotide polymorphisms, because they did not have normal controls to call tumor-specific variants. In comparison, 1 sample in our study harbored an ARID1A mutation, with a variant allele frequency of 4.5%.
Another interesting candidate reported was the DDR1 gene, mutated in 11% of the tumors. 3 However, only 1 tumor in our study harbored a DDR1 mutation. Similarly, the candidate gene CDC27 from our study was only mutated in 1 of 26 exome-sequenced samples, and USP8 was not mutated in any. Still, the low frequency of candidate genes reported in the current study and by Agnihotri et al. might represent important tumorigenic factors in subsets of schwannomas. The authors also identified enrichment of mutations in both known and novel VS pathways, although the axonal guidance pathway, reported in our study, was not among them.
The transcript of the CAV1 gene has shown it to be universally downregulated in sVSs, 1, 61 but none of the 46 VSs investigated in the present study harbored mutations in the CAV1 gene. We therefore sought to investigate whether the mutational hits found in this study could explain the absence of CAV1 mRNA in sVSs. Using an in silico-based approach, we discovered many plausible links between our gene set and molecules upstream of CAV1. Of note, NF2 and several nodes linking to the ERK signaling pathway might regulate CAV1 expression. Other mechanisms, such as epigenetic silencing (not investigated in this study), might also govern the expression of this gene.
The extent of resection was total in 20, near total in 24, and subtotal in 2 patients. Six of 8 patients with poor postoperative facial function had total resection. We therefore assume that resection rate and facial function were primarily determined by the surgeon's decision to remove the entire tumor. We did not find any specific mutation correlating with the extent of resection, postresection facial nerve function, or progression-free survival.
The outlier specimen was from the oldest patient in the study (75 years of age). The tumor was resected in 2013, needed retreatment the same year with GKRS because of rapid regrowth, and needed retreatment with microsurgery in 2016, exhibiting an aggressive phenotype. This tumor harbored a missense mutation (c.A62G, p.D21G) in the RAD54 L gene. The protein encoded by this gene belongs to the DEAD-like helicase superfamily and is involved in the homologous recombination and repair of DNA. Mutations in this gene have previously been implicated in tumorigenesis and induction of genome instability. 21, 50 On the basis of this finding, we decided to investigate our 46 sVSs for MSI, a functional assay demonstrating replication error. A previous study found MSI in 2 of 11 VSs; however, they found it to be associated with spinal schwannomas and not intracranial ones. 55 None of the tumors in our study demonstrated MSI, establishing this phenomenon as being rare in sVS. However, the outlier might have still harbored a large number of variants due to impairment of DNA repair mechanisms not resulting in MSI.
We speculate that the correlation with the clinical behavior might be more than a coincidence. We assume that this tumor harbored a large proportion of passenger mutations as opposed to driver mutations. This could have precluded the discovery of clustering of mutations in signaling pathways and other relevant functions. Our study thus highlights the importance of taking mutations in DNA repair genes into account when performing pathway analyses on gene sets from tumor-normal pairs for the discovery of tumorigenesis-related genes.
In this study, we identified a large number of tumorspecific mutations. However, it is believed that for a clone of cells to develop growth advantages that are sufficient to make a tumor, relatively few products relevant for the hallmarks of cancer need to be disrupted. 18, 23 Thus, distinguishing the true driver mutations responsible for tumorigenesis from the passenger mutations remains a great challenge. 42, 59 In particular, we suspect that the outlier harbored a disproportionate amount of passenger mutations. This was also excluded from some of the analysis regarding identification of clustering of mutations in relevant signaling pathways, because the large number of passenger mutations would have diluted the driver mutations. Using a combination of frequency-and functional-based approaches, we identified some novel genes and lent support to the involvement of previously implicated pathways as well as novel pathways. In particular, the axonal guidance pathway seems to be involved in sVS tumorigenesis.
Conclusions
We believe that our work represents the largest WES study on schwannomas. In conclusion, this study supports the view that NF2 is the most central factor in VS tumorigenesis. In addition, the axonal guidance pathway, CDC27, and USP8 are suggested as novel tumorigenic factors. Interestingly, GKRS did not induce hypermutation of the tumor.
